Marie Brodbeck

Marie Brodbeck

Marie is a graduate of Duquesne University and has been a finance journalist for over a decade, when she began writing macroeconomic articles on a freelance basis. Since then, she has traveled the world and has been able to fund her lifestyle through a combination of savvy investments and frugal finances. She believes in taking risks when the market is fearful but always investing with a long-term view in mind.

Recent Articles

3 Oil and Gas Stocks That Will Help You Strike It Rich

The best oil and gas stocks to buy are those that have been preparing for the future while times have been good.

3 Top Stock Picks to Profit From the Telehealth Boom

There are plenty of choices for telehealth stocks to buy, but these three offer some of the most compelling stories.

3 Top Losers of 2022 That Will Sink AGAIN in 2023

Turnaround stocks can be enticing, but the current conditions mean you're more likely to come up with stocks to avoid.

3 Education Stocks Headed to the Principal’s Office

Education stocks have leaned heavily toward e-learning over the past year but as the pandemic eases this trend could start to reverse.

DraftKings Could Win Big as Further Legalization Improves Odds

DKNG stock is on a solid path to profitability as long as management can execute and legalization continues.

Virgin Galactic Stock Could Be Worth the Gamble, But We Won’t Know for Years

It's unclear whether commercial space travel will ever be profitable, but SPCE stock's going to try

Advanced Micro Devices Is in a Strong Spot

AMD stock may look expensive on the surface, but Advanced Micro Devices maker is actually fairly valued compared to semiconductor peers.

Peloton Stock Looks to Be Just Spinning Its Wheels at This Point

PTON stock still has a lot to prove before it will be a good investment-- the bike price cut is a step in the right direction, but the proof's in the pudding. If bikes don't fly off shelves this winter, the business could be in trouble.

Pfizer is a Clear Covid-19 Winner. Is That Enough?

Pfizer was strong before Covid-19 hit, but now it's on steroids. The valuation of PFE stock doesn't reflect the opportunity that lies ahead.

Lemonade Stock Is a Sweet Idea with Sour Finances Sending Up Red Flags

LMND stock appeals as a potential disruptor, particularly considering it's appeal to the younger generation. But it's not all sweet when it comes to the group's finances and path to profitability.